# mybacs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mybacs

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.mybacs.co
- Total disclosed funding: $5.9M
- Latest round: Series A (Oct 26, 2023)
- Investors on record: 5

## About

mybacs GmbH is a Swiss company specializing in high-quality dietary supplements that enhance gut microbiome health through a diverse range of probiotics, prebiotics, and postbiotics aimed at improving overall health.Founded in 2018 in Zug, Switzerland, mybacs GmbH focuses on developing dietary supplements for gut health. The company has successfully closed 3 funding deals, with the latest being a Series A round in October 2023, raising EUR 5.6 million, led by naturalX Health Ventures. The founders include Adrian Weingart, Carl-Philipp von Polheim, and Sebastian Wahl, with Carl-Philipp von Polheim currently serving as CEO.mybacs® specializes in high-quality dietary supplements aimed at enhancing gut microbiome health. The company offers a diverse range of probiotic, prebiotic, and postbiotic products, scientifically formulated to support digestion, immune function, metabolism, skin health, and mental well-being. Key offerings include the Dailybacs® for women and the Nutribacs®, a micronutrient concentrate combining multiple beneficial ingredients, primarily marketed in Germany, Spain, and Switzerland to health-conscious consumers.mybacs® generates revenue through a subscription-based model, allowing for regular deliveries of dietary supplements. Individual products start from approximately EUR 39.95 for the Dailybacs®, with varying prices based on product complexity. This direct-to-consumer approach fosters a loyal customer base, supported by promotional strategies that enhance customer engagement and loyalty.In October 2023, mybacs GmbH raised EUR 5.6 million in Series A funding, led by naturalX Health Ventures, with participation from SevenVentures and WENVEST Capital, alongside returning investors Global Founders Capital and Joyance Partners. The funding will be directed towards developing symbiotic nutritional supplements, as the company aims to expand its product line and enter new markets in the near future.

## Funding rounds

- Series A, Oct 26, 2023, $5.9M — Global Founders Capital, SevenVentures, Joyance Partners, WENVEST Capital, naturalX Health Ventures
- Seed, Aug 29, 2019 — Global Founders Capital

## Investors

- Global Founders Capital (https://capitalatlas.ai/funds/global-founders-capital) — Seed, Series A
- SevenVentures (https://capitalatlas.ai/funds/sevenventures) — Series A
- Joyance Partners (https://capitalatlas.ai/funds/joyance-partners) — Series A
- WENVEST Capital (https://capitalatlas.ai/funds/wenvest-capital) — Series A
- naturalX Health Ventures (https://capitalatlas.ai/funds/naturalx-health-ventures) — Series A